InvestSMART

Little Green Pharma Ltd (ASX:LGP)

ALERT: Price-sensitive ASX Announcement for LGP
Current share price for LGP : $0.058 -0.002 (-3.33%)+
Announcement
Release
30 Oct 2026 5:10PM
Price at Release
$0.060
Full Release
download
Summary
Little Green Pharma Ltd’s Quarterly Activities Report and Appendix 4C for the quarter ended 30 September 2026 describes the first full quarter of combined trading following its 1 June 2026 merger with Cannatrek Ltd, reporting unaudited revenue of $26.0 million, receipts from customers of $26.8 million, net operating cash inflow of $4.4 million and a closing cash balance of $22.3 million, with total borrowings excluding leases of $5.2 million; flower accounted for 81% of group sales, Australia represented 82% of sales and Europe 18%, and brand mix was approximately 65% Cannatrek and 35% LGP, while post-merger initiatives targeting $3.0 million in annualised cost synergies were actioned through inventory consolidation, supplier onboarding, merged customer support, licence alignment and IT integration; the report also highlights investment in the Danish facility to improve yields, efficiency and capacity, progress in Europe including German market expansion, UK expansion with a London office, a new Country Manager and advancing clinic and wholesale partnerships, plus developments in France and Italy, alongside corporate updates covering the post-quarter sale of Health House International, appointment of Pitcher Partners as auditor and regulatory reform in NSW permitting eligible medicinal cannabis patients to drive with prescribed THC in their system from early 2027 if not impaired.
Key Points
  • Quarter ended 30 September 2026 was the first full quarter reflecting combined LGP and Cannatrek trading after the 1 June 2026 merger.
  • Unaudited revenue for the quarter was $26.0 million.
  • Net cash inflow from operating activities was $4.4 million.
  • Closing cash balance at 30 September 2026 was $22.3 million.
  • Receipts from customers were $26.8 million.
  • Product manufacturing and operating costs were $15.0 million.
  • Staff costs were $4.3 million and included $0.2 million of one-off restructuring costs.
  • Administration and corporate costs were $3.4 million.
  • Payments to related parties totalled $0.2 million and related to directors.
  • Total borrowings excluding leases were $5.2 million at quarter end.
  • Flower represented 81% of group sales, with oils at 11%, edibles at 4% and vapes at 4%.
  • Australia accounted for 82% of sales and Europe including EU and UK accounted for 18%.
  • Brand contribution was about 65% Cannatrek and 35% LGP, with Cornerfield growing 14% on the prior quarter.
  • Post-merger cost synergy initiatives targeting $3.0 million per annum were actioned.
  • LGP Australian inventory was consolidated at the Shepparton facility and customer support functions were merged.
  • LGP Australia went live on the Group ERP on 1 October 2026 and further CRM and M365 integration was progressing.
  • The Danish facility investment program was underway, including under-canopy lighting rollout and post-harvest equipment upgrades to improve yield and lower cost per gram.
  • In Germany, medicinal cannabis flower imports reached a record 67.6 tonnes in Q1 2026, and LGP was progressing appointment of a Country Manager.
  • In the UK, the company opened a London office, appointed Karen Bowell as Country Manager and advanced clinic and wholesale partnerships under a three-year growth plan.
  • LGP expected UK clinic operations under a strategic partnership to commence in the second half of FY27.
  • In France, dossier applications were expected before the end of calendar 2026, subject to the regulatory environment.
  • A shipment was delivered to Italy after quarter end.
  • Subsequent to quarter end, LGP sold Health House International to Medicann Health Australia.
  • Pitcher Partners was appointed as group auditor following BDO Audit Pty Ltd's resignation.
  • NSW passed legislation in September 2026 to allow eligible medicinal cannabis patients to drive with prescribed THC in their system from early 2027 if not impaired.
  • Total available funding including unused facilities was $31.5 million at quarter end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.